Trimetazidine-Induced Parkinsonism: A Systematic Review

Anna Marielle B Dy; Lorenzo Luis G Limjoco; Roland Dominic G Jamora

doi:10.3389/fneur.2020.00044

Trimetazidine-Induced Parkinsonism: A Systematic Review

Front Neurol. 2020 Feb 25:11:44. doi: 10.3389/fneur.2020.00044. eCollection 2020.

Authors

Anna Marielle B Dy^{1

2}, Lorenzo Luis G Limjoco³, Roland Dominic G Jamora^{2

4

5}

Affiliations

¹ Department of Clinical Neurosciences, University of the East Ramon Magsaysay Memorial Medical Center, Inc., Quezon City, Philippines.
² Section of Neurology, Department of Internal Medicine, Cardinal Santos Medical Center, San Juan, Philippines.
³ Department of Surgery, Rizal Medical Center, Pasig, Philippines.
⁴ Movement Disorder Service and Section of Neurology, Institute for Neurosciences, St. Luke's Medical Center, Quezon, Philippines.
⁵ Department of Neurosciences, College of Medicine - Philippine General Hospital, University of the Philippines Manila, Manila, Philippines.

Abstract

Importance: Trimetazidine (TMZ) is a medication given to patients with stable coronary artery disease. While it is reportedly well-tolerated, there are increasing numbers of reports of adverse events such as parkinsonism. Objectives: The purpose of this study was to systematically review the currently available literature on TMZ-induced parkinsonism. Evidence Review: A search of Scopus, MEDLINE, EMBASE, the Cochrane Library, the Health Technology Assessment Database, PubMed, Science Direct, and Google Scholar was conducted on or before November 7, 2019. The literature search included cohort studies, prospective and/or retrospective studies, meta-analysis, and other systematic reviews published as an original article, including abstracts and full texts. We included patients taking TMZ who developed one or more of the parkinsonian symptoms of bradykinesia, tremors, rigidity, and postural instability, where these symptoms improved after withdrawal of the said medication. Findings: There are currently five studies on TMZ use and associated parkinsonism. The literature included two case reports, one case series, and one retrospective and one prospective study. We found no results from randomized clinical trials. Overall, 88 patients developed TMZ-induced parkinsonism. Regression of parkinsonism was reported in all of the participants after withdrawal of TMZ. A total of 49 patients (55.7%) had complete regression of symptoms, while 39 patients (44.3%) had significant reduction of symptoms. The duration between TMZ (dose, 60-80 mg/day) intake and onset of symptoms ranged from 4 months to 20 years. The most commonly reported extrapyramidal symptoms were akinesia, rigidity, postural disturbances, and gait disorders, which were usually mild and symmetric. Conclusions and Relevance: The current literature suggests that TMZ can induce parkinsonism that is reversible with drug withdrawal. It is warranted to examine patients, especially the elderly, on TMZ for parkinsonian symptoms and those with pre-existing neurodegenerative diseases. Further studies are needed to assess the risk-benefit ratio of this drug, especially in the elderly age group.

Keywords: drug-induced; parkinsonism; reversible parkinsonism; trimetazidine; trimetazidine-induced parkinsonism.

Publication types

Systematic Review